Identification of alpha 2-macroglobulin as a carrier protein for IL-6.

PubWeight™: 1.36‹?› | Rank: Top 10%

🔗 View Article (PMID 2462586)

Published in J Immunol on January 01, 1989

Authors

T Matsuda1, T Hirano, S Nagasawa, T Kishimoto

Author Affiliations

1: Division of Cellular Immunology, Osaka University, Japan.

Articles citing this

Interleukin-6 and the acute phase response. Biochem J (1990) 7.97

Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg (1996) 2.24

Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol (1999) 2.15

ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci (2008) 2.09

Acute-phase reaction induces a specific complex between hepatic nuclear proteins and the interleukin 6 response element of the rat alpha 2-macroglobulin gene. Proc Natl Acad Sci U S A (1990) 1.66

Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut (1995) 1.31

The extracellular regulation of growth factor action. Mol Biol Cell (1992) 1.25

Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut (1992) 1.24

Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med (1991) 1.01

Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis (1992) 0.97

Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulin. Am J Pathol (1991) 0.95

Binding of transforming growth factor-beta 1 to methylamine-modified alpha 2-macroglobulin and to binary and ternary alpha 2-macroglobulin-proteinase complexes. Biochem J (1992) 0.89

Multiplex cytokine concentration measurement: how much do the medium and handling matter? Mediators Inflamm (2013) 0.82

Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: the role of cytokines. Br J Pharmacol (2000) 0.81

Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci (2007) 0.81

Differences in the binding of transforming growth factor beta 1 to the acute-phase reactant and constitutively synthesized alpha-macroglobulins of rat. Biochem J (1995) 0.81

Hepcidin bound to α2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. J Biol Chem (2013) 0.79

Comparison between the protective effects of mycobacterial 65-kD heat shock protein and ovomucoid in pristane-induced arthritis: relationship with agalactosyl IgG. Clin Exp Immunol (1993) 0.78

Concentration of fetal plasma and amniotic fluid interleukin-1 in pregnancies complicated by preterm prelabour amniorrhexis. J Clin Pathol (1995) 0.77

Evaluation of plasma alpha-2-macroglobulin and interactions with tumour necrosis factor-alpha in horses with endotoxemic signs. Can J Vet Res (1996) 0.77

Alpha2-macroglobulin as a promising biomarker for cerebral small vessel disease in acute ischemic stroke patients. J Neurol (2013) 0.76

Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines. Br J Cancer (1997) 0.76

Alpha-2-macroglobulin as a radioprotective agent: a review. Chin J Cancer Res (2014) 0.75

Role of Biomarkers as Predictors of Infection and Death in Neutropenic Febrile Patients after Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis (2015) 0.75

Binding of lipoprotein lipase to alpha 2-macroglobulin. Biochem J (1994) 0.75

Articles by these authors

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63

A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17

Engineered GFP as a vital reporter in plants. Curr Biol (1996) 9.03

Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85

Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38

Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med (2000) 6.68

Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56

Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45

The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18

Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02

Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. Genes Dev (1998) 5.78

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72

Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60

Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20

Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17

Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16

Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93

Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74

Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70

Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51

Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34

Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med (1999) 4.33

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31

Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25

Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23

Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06

IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03

ATP-dependent positive supercoiling of DNA by 13S condensin: a biochemical implication for chromosome condensation. Cell (1997) 3.95

Phosphorylation and activation of 13S condensin by Cdc2 in vitro. Science (1998) 3.89

Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res (2000) 3.86

Molecular regulation of B lymphocyte response. Annu Rev Immunol (1988) 3.68

Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66

Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64

Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59

Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46

A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 3.40

Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell (1986) 3.34

Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn (1999) 3.33

Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31

Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28

IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol (2003) 3.26

13S condensin actively reconfigures DNA by introducing global positive writhe: implications for chromosome condensation. Cell (1999) 3.24

IL-6 is produced by osteoblasts and induces bone resorption. J Immunol (1990) 3.14

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13

Chemical nature of the light emitter of the Aequorea green fluorescent protein. Proc Natl Acad Sci U S A (1996) 3.12

IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol (2000) 3.08

Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun (1999) 3.03

Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01

Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. Dev Biol (2000) 2.93

LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93

Identification and characterization of SA/Scc3p subunits in the Xenopus and human cohesin complexes. J Cell Biol (2000) 2.91

Non-invasive quantitative detection and applications of non-toxic, S65T-type green fluorescent protein in living plants. Plant J (1999) 2.88

B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86

CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 2.83

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone (2001) 2.81

IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev (1992) 2.80

Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J (1997) 2.80

AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1990) 2.79

Factors affecting B-cell growth and differentiation. Annu Rev Immunol (1985) 2.78

Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A (1987) 2.76

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75

Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A (1996) 2.70

Xenopus M phase MAP kinase: isolation of its cDNA and activation by MPF. EMBO J (1991) 2.68

HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. Genome Res (2000) 2.66

Rheumatoid factor secretion from human Leu-1+ B cells. Science (1987) 2.65

STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64

Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun (2001) 2.63

Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood (1992) 2.62

Transmission of bacteriocinogenicity by conjugation in group D streptococci. Jpn J Microbiol (1973) 2.60

Xklp1, a chromosomal Xenopus kinesin-like protein essential for spindle organization and chromosome positioning. Cell (1995) 2.57

A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc Natl Acad Sci U S A (1992) 2.55

T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol (1981) 2.46

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett (1989) 2.43

Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4bINA cofactor) and production of a new C3b derivative (C3b'). Immunochemistry (1978) 2.43

Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. Eur J Immunol (1988) 2.41